Publications

1. Sinicrope FA, Nelson GD, Saberzadeh-Ardestani B, Segovia DI, Graham RP, Wu C, Hagen CE, Shivji S, Savage P, Buchanan DD, Jenkins MA, Phipps AI, Swallow C, LeMarchand L, Gallinger S, Grant RC, Pai RK, Sinicrope SN, Yan D, Shanmugam K, Conner J, Cyr DP, Kirsch R, Banerjee I, Alberts SR, Shi Q, Pai RK. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence. Cancer Res Commun. 2024 May 23; 4 (5):1344-1350
   View PubMed
2. Wu C, Pai RK, Kosiorek H, Banerjee I, Pfeiffer A, Hagen CE, Hartley CP, Graham RP, Sonbol MB, Bekaii-Saab T, Xie H, Sinicrope FA, Patel B, Westerling-Bui T, Shivji S, Conner J, Swallow C, Savage P, Cyr DP, Kirsch R, Pai RK. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC. Clin Cancer Res. 2024 May 1; 30 (9):1811-1821
   View PubMed
3. Gallois C, Shi Q, Pederson LD, Andre T, Iveson TJ, Sobrero AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, Oki E, Shields AF, Boukovinas I, Kerr R, Lonardi S, Yothers G, Yoshino T, Goldberg RM, Taieb J, Papamichael D. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. J Clin Oncol. 2024 Mar 28; JCO2301326 [Epub ahead of print]
   View PubMed
4. Chung DC, Gray DM 2nd, Singh H, Issaka RB, Raymond VM, Eagle C, Hu S, Chudova DI, Talasaz A, Greenson JK, Sinicrope FA, Gupta S, Grady WM. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14; 390 (11):973-983
   View PubMed
5. Escuder-Rodriguez JJ, Liang D, Jiang X, Sinicrope FA. Ferroptosis: Biology and Role in Gastrointestinal Disease. Gastroenterology. 2024 Mar 1 Epub 2024 Mar 01
   View PubMed
6. Emiloju OE, Storandt M, Zemla T, Tran N, Jethwa K, Mahipal A, Mitchell J, Thiels C, Mathis K, McWilliams R, Hubbard J, Sinicrope F, Shi Q, Jin Z. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. JCO Precis Oncol. 2024 Jan; 8:e2300127
   View PubMed
7. Saberzadeh-Ardestani B, Jones JC, McWilliams RR, Tougeron D, Halfdanarson TR, Guimbaud R, Hubbard JM, Flecchia C, Shi Q, Alouani E, Sonbol MB, Ticku J, Jin Z, Taieb J, Sinicrope FA. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting. Eur J Cancer. 2024 Jan; 196:113433 Epub 2023 Nov 10
   View PubMed
8. Emiloju OE, Zhu M, Xie H, Jin Z, Sinicrope FA, Hubbard JM. Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer. Curr Treat Options Oncol. 2023 Dec; 24 (12):1739-1757 Epub 2023 Nov 15
   View PubMed
9. Emiloju OE, Sinicrope FA. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer: A Review. JAMA Oncol. 2023 Dec 1; 9 (12):1708-1715
   View PubMed
10. Taieb J, Sinicrope FA, Pederson L, Lonardi S, Alberts SR, George TJ, Yothers G, Van Cutsem E, Saltz L, Ogino S, Kerr R, Yoshino T, Goldberg RM, Andre T, Laurent-Puig P, Shi Q. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials. Ann Oncol. 2023 Nov; 34 (11):1025-1034 Epub 2023 Aug 23
    View PubMed
11. Saberzadeh-Ardestani B, Graham RP, McMahon S, Ahanonu E, Shi Q, Williams C, Hubbard A, Zhang W, Muranyi A, Yan D, Jin Z, Shanmugam K, Sinicrope FA. Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced Colorectal Carcinomas. Clin Cancer Res. 2023 Oct 13; 29 (20):4268-4277
    View PubMed
12. Gallois C, Landi M, Taieb J, Sroussi M, Saberzadeh-Ardestani B, Cazelles A, Lonardi S, Bergamo F, Intini R, Maddalena G, Pietrantonio F, Corti F, Ambrosini M, Martinetti A, Germani MM, Boccaccio C, Vetere G, Mouillet-Richard S, de Reynies A, Sinicrope FA, Cremolini C, Laurent-Puig P. Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors. Clin Cancer Res. 2023 Sep 15; 29 (18):3771-3778
    View PubMed
13. Storandt MH, Rogen KR, Iyyangar A, Schnell RR, Mitchell JL, Hubbard JM, Sinicrope FA, Jatoi A, Mahipal A, Shi Q, Jin Z. Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis. Cancers (Basel). 2023 Jul 11; 15 (14) Epub 2023 July 11
    View PubMed
14. Emiloju OE, Saberzadeh-Ardestani B, Sinicrope FA. Synchronous Neoplasia Rates at Colonoscopic Diagnosis of Early-Onset vs Average-Onset Colorectal Cancer. JAMA Netw Open. 2023 Jul 3; 6 (7):e2324038 Epub 2023 July 03
    View PubMed
15. Sun L, Yu J, Guinney J, Qin B, Sinicrope FA. USP10 Regulates ZEB1 Ubiquitination and Protein Stability to Inhibit ZEB1-Mediated Colorectal Cancer Metastasis. Mol Cancer Res. 2023 Jun 1; 21 (6):578-590
    View PubMed
16. Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, Andre T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2023 Feb 1; 41 (4):803-815 Epub 2022 Oct 28
    View PubMed
17. Saberzadeh-Ardestani B, Jones JC, Hubbard JM, McWilliams RR, Halfdanarson TR, Shi Q, Sonbol MB, Ticku J, Jin Z, Sinicrope FA. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. JAMA Netw Open. 2023 Feb 1; 6 (2):e230400 Epub 2023 Feb 01
    View PubMed
18. Saberzadeh-Ardestani B, Foster NR, Lee HE, Shi Q, Alberts SR, Smyrk TC, Sinicrope FA. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]. Ann Oncol. 2022 Nov; 33 (11):1159-1167 Epub 2022 Aug 10
    View PubMed
19. Jin Z, Sinicrope FA. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. J Clin Oncol. 2022 Aug 20; 40 (24):2735-2750 Epub 2022 June 01
    View PubMed
20. Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. JCO Precis Oncol. 2022 Aug; 6:e2200010
    View PubMed
21. Christou N, Bergen ES, Canton C, Le Malicot K, Di Bartolomeo M, Galli F, Galli F, Labianca R, Shi Q, Alberts SR, Goldberg RM, Lepage C, Sinicrope FA, Taieb J. Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials. Eur J Cancer. 2022 May; 166:100-111 Epub 2022 Mar 11
    View PubMed
22. Sinicrope FA. Increasing Incidence of Early-Onset Colorectal Cancer. N Engl J Med. 2022 Apr 21; 386 (16):1547-1558
    View PubMed
23. Sinicrope FA. The author replies:. New England Journal of Medicine. 2022; 387 (1):93-4
    
24. Jin Z, Dixon JG, Fiskum JM, Parekh HD, Sinicrope FA, Yothers G, Allegra CJ, Wolmark N, Haller D, Schmoll HJ, de Gramont A, Kerr R, Taieb J, Van Cutsem E, Tweleves C, O'Connell M, Saltz LB, Sadahiro S, Blanke CD, Tomita N, Seitz JF, Erlichman C, Yoshino T, Yamanaka T, Marsoni S, Andre T, Mahipal A, Goldberg RM, George TJ, Shi Q. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. J Natl Cancer Inst. 2021 Nov 29; 113 (12):1693-1704
    View PubMed
25. Sinicrope FA, Shi Q, Smyrk TC, Goldberg RM, Cohen SJ, Gill S, Kahlenberg MS, Nair S, Shield AF, Jahagirdar BN, Jacobson SB, Foster NR, Pollak MN, Alberts SR. Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. JNCI Cancer Spectr. 2021 Oct; 5 (5) Epub 2021 July 23
    View PubMed
26. Sun L, Patai AV, Hogenson TL, Fernandez-Zapico ME, Qin B, Sinicrope FA. Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer. Oncogene. 2021 Aug; 40 (32):5105-5115 Epub 2021 June 30
    View PubMed
27. Sinicrope FA, Graham RP. Tumor-Infiltrating Lymphocytes for Prognostic Stratification in Nonmetastatic Colon Cancer-Are We There Yet? JAMA Oncol. 2021 Jul 1; 7 (7):969-970
    View PubMed
28. Sinicrope FA, Viggiano TR, Buttar NS, Song LMWK, Schroeder KW, Kraichely RE, Larson MV, Sedlack RE, Kisiel JB, Gostout CJ, Kalaiger AM, Patai AV, Della'Zanna G, Umar A, Limburg PJ, Meyers JP, Foster NR, Yang CS, Sontag S. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia. Cancer Prev Res (Phila). 2021 May; 14 (5):573-580 Epub 2021 Mar 01
    View PubMed
29. Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, Andre T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol. 2021 Feb 20; 39 (6):642-651 Epub 2020 Dec 23
    View PubMed
30. Sinicrope FA, Chakrabarti S, Laurent-Puig P, Huebner L, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Zaanan A, Folprecht G, Van Laethem JL, Le Malicot K, Shi Q, Alberts SR, Taieb J. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. Eur J Cancer. 2021 Feb; 144:101-112 Epub 2020 Dec 17
    View PubMed
31. Labadie JD, Hua X, Harrison TA, Banbury BL, Huyghe JR, Sun W, Shi Q, Yothers G, Alberts SR, Sinicrope FA, Goldberg RM, George TJ, Penney KL, Phipps AI, Cohen SA, Peters U, Chan AT, Newcomb PA. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev. 2021 Feb; 30 (2):404-411 Epub 2020 Nov 17
    View PubMed
32. Jin Z, Sinicrope FA. Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. Cancers (Basel). 2021 Jan 15; 13 (2)
    View PubMed
33. Ballester V, Taylor WR, Slettedahl SW, Mahoney DW, Yab TC, Sinicrope FA, Boland CR, Lidgard GP, Cruz-Correa MR, Smyrk TC, Boardman LA, Ahlquist DA, Kisiel JB. Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia. Epigenomics. 2020 Dec; 12 (24):2173-2187 Epub 2020 Dec 22
    View PubMed
34. Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020 Dec; 10 (12):1808-1825 Epub 2020 Nov 02
    View PubMed
35. Penney KL, Banbury BL, Bien S, Harrison TA, Hua X, Phipps AI, Sun W, Song M, Joshi AD, Alberts SR, Allegra CJ, Atkins J, Colangelo LH, George TJ, Goldberg RM, Lucas PC, Nair SG, Shi Q, Sinicrope FA, Wolmark N, Yothers G, Peters U, Newcomb PA, Chan AT. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. Clin Gastroenterol Hepatol. 2020 Nov; 18 (12):2717-2723.e3 Epub 2019 Dec 04
    View PubMed
36. Burke CA, Dekker E, Lynch P, Samadder NJ, Balaguer F, Huneburg R, Burn J, Castells A, Gallinger S, Lim R, Stoffel EM, Gupta S, Henderson A, Kallenberg FG, Kanth P, Roos VH, Ginsberg GG, Sinicrope FA, Strassburg CP, Van Cutsem E, Church J, Lalloo F, Willingham FF, Wise PE, Grady WM, Ford M, Weiss JM, Gryfe R, Rustgi AK, Syngal S, Cohen A. Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. N Engl J Med. 2020 Sep 10; 383 (11):1028-1039
    View PubMed
37. Lanzi A, Sinicrope FA, Benson AB, Galon J. The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions. Oncoimmunology. 2020 Jul 20; 9 (1):1796003 Epub 2020 July 20
    View PubMed
38. Sinicrope FA, Shi Q, Hermitte F, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectr. 2020 Jun; 4 (3):pkaa023 Epub 2020 Apr 05
    View PubMed
39. Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala R, Cripps C, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB 3rd. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). Oncologist. 2020 May; 25 (5):e798-e807 Epub 2019 Dec 18
    View PubMed
40. Lee H, Sha D, Foster NR, Shi Q, Alberts SR, Smyrk TC, Sinicrope FA. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Ann Oncol. 2020 Apr; 31 (4):487-494 Epub 2020 Jan 25
    View PubMed
41. Specogna AV, Sinicrope FA. Defining colon cancer biomarkers by using deep learning. Lancet 2020 Feb 1; 395 (10221):314-316
    View PubMed
42. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. JCO Precis Oncol. 2020; 4 Epub 2020 Feb 26
    View PubMed
43. Chakrabarti S, Huebner LJ, Finnes HD, Muranyi A, Clements J, Singh S, Hubbard JM, McWilliams RR, Shanmugam K, Sinicrope FA. Intratumoral CD3(+) and CD8(+) T-Cell Densities in Patients With DNA Mismatch Repair-Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade. JCO Precis Oncol. 2019 Dec; 3:1-7
    View PubMed
44. Sinicrope FA, Velamala PR, Song LMWK, Viggiano TR, Bruining DH, Rajan E, Gostout CJ, Kraichely RE, Buttar NS, Schroeder KW, Kisiel JB, Larson MV, Sweetser SR, Sedlack RR, Sinicrope SN, Richmond E, Umar A, Della'Zanna G, Noaeill JS, Meyers JP, Foster NR. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms. Cancer Prev Res (Phila). 2019 Nov; 12 (11):821-830 Epub 2019 Sept 04
    View PubMed
45. Feng D, Qin B, Pal K, Sun L, Dutta S, Dong H, Liu X, Mukhopadhyay D, Huang S, Sinicrope FA. BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene. 2019 Oct; 38 (41):6752-6766 Epub 2019 Aug 12
    View PubMed
46. Jin Z, Sinicrope FA. Advances in the therapy of BRAF(V600E) metastatic colorectal cancer. Expert Rev Anticancer Ther. 2019 Sep; 19 (9):823-829 Epub 2019 Sept 04
    View PubMed
47. Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, Andre T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019 Sep 1; 30 (9):1466-1471
    View PubMed
48. Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, Andre T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019 Sep; 30 (9):1466-1471 Epub 2019 Dec 12
    View PubMed
49. Song M, Ou FS, Zemla TJ, Hull MA, Shi Q, Limburg PJ, Alberts SR, Sinicrope FA, Giovannucci EL, Van Blarigan EL, Meyerhardt JA, Chan AT. Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). Int J Cancer. 2019 Jul 15; 145 (2):380-389 Epub 2019 Jan 28
    View PubMed
50. Chakrabarti S, Huebner LJ, Finnes HD, Muranyi A, Clements J, Singh S, Hubbard JM, McWilliams RR, Shanmugam K, Sinicrope FA. Intratumoral cd3(+) and cd8(+) t-cell densities in patients with dna mismatch repair-deficient metastatic colorectal cancer receiving programmed cell death-1 blockade JCO Precision Oncology. 2019 Jun 28; 3:1-7
    
51. Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, Ling YH, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, Dignam JJ, Kerr DJ, Rosell R, Mao M, Li JB, Guo YM, Wu XY, Kong LH, Tang JH, Wu XD, Li CF, Chen JR, Ou QJ, Ye MZ, Guo FM, Han P, Wang Q, Wan DS, Li L, Xu RH, Pan ZZ, Ding PR, Written on behalf of AME Colorectal Cancer Cooperative Group. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. Int J Cancer. 2019 May 1; 144 (9):2161-2168 Epub 2019 Jan 09
    View PubMed
52. Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, Djalilvand A, Clements J, Bowermaster R, Liu WW, Barnes M, Alberts SR, Shanmugam K, Sinicrope FA. Intertumoral Heterogeneity of CD3(+) and CD8(+) T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. Clin Cancer Res. 2019 Jan 1; 25 (1):125-133 Epub 2018 Oct 09
    View PubMed
53. Gleeson FC, Levy MJ, Roden AC, Boardman LA, Sinicrope FA, McWilliams RR, Zhang L. EUS fine-needle pancreatic core biopsy can determine eligibility for tumor-agnostic immunotherapy. Endosc Int Open. 2018 Oct; 6 (10):E1278-E1282 Epub 2018 Oct 08
    View PubMed
54. Sinicrope FA. Lynch Syndrome-Associated Colorectal Cancer. N Engl J Med. 2018 Aug 23; 379 (8):764-773
    View PubMed
55. Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA, Shields A, Sinicrope FA, Sargent DJ, Alberts SR. Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 Jun; 27 (6):696-703 Epub 2018 Mar 21
    View PubMed
56. Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, Huang S, Sinicrope FA. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Mol Cancer Res. 2018 Mar; 16 (3):378-389 Epub 2017 Dec 12
    View PubMed
57. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA Oncol. 2018 Mar 1; 4 (3):379-383
    View PubMed
58. Pitari GM, Cotzia P, Ali M, Birbe R, Rizzo W, Bombonati A, Palazzo J, Solomides C, Shuber AP, Sinicrope FA, Zuzga DS. Vasodilator-Stimulated Phosphoprotein Biomarkers Are Associated with Invasion and Metastasis in Colorectal Cancer. Biomark Cancer. 2018; 10:1179299X18774551 Epub 2018 June 05
    View PubMed
59. Sinicrope FA, Shi Q, Alberts SR. Mutation in BRAF V600E-Reply. JAMA Oncol 2017 Sep 1; 3 (9):1285-1286
    View PubMed
60. Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouche O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2017 May; 109 (5) Epub 2016 Dec 31
    View PubMed
61. Rashtak S, Rego R, Sweetser SR, Sinicrope FA. Sessile Serrated Polyps and Colon Cancer Prevention. Cancer Prev Res (Phila). 2017 May; 10 (5):270-278 Epub 2017 Mar 21
    View PubMed
62. Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017 May 1; 28 (5):1023-1031
    View PubMed
63. Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2017 Apr 1; 3 (4):472-480
    View PubMed
64. Miyoshi J, Toden S, Yoshida K, Toiyama Y, Alberts SR, Kusunoki M, Sinicrope FA, Goel A. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep. 2017 Mar 6; 7:43393 Epub 2017 Mar 06
    View PubMed
65. Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017 Feb 09;
    View PubMed
66. Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, Jahagirdar B, Goldberg RM, Alberts SR. Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). J Gastrointest Oncol. 2017 Feb; 8 (1):1-11
    View PubMed
67. Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist. 2016 Dec; 21 (12):1509-1521 Epub 2016 Nov 23
    View PubMed
68. Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Mol Cancer Ther. 2016 Dec; 15 (12):3015-3027 Epub 2016 Oct 07
    View PubMed
69. Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Int J Cancer. 2016 Oct 1; 139 (7):1626-31 Epub 2016 June 10
    View PubMed
70. Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR, Alliance for Clinical Trials in Oncology. Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. Int J Cancer. 2016 Sep 1; 139 (5):986-95 Epub 2016 May 09
    View PubMed
71. Sinicrope FA. The role of microsatellite instability testing in management of colorectal cancer. Clin Adv Hematol Oncol. 2016 Jul; 14: (7)476-9.
    View PubMed
72. Sweetser S, Jones A, Smyrk TC, Sinicrope FA. Sessile Serrated Polyps are Precursors of Colon Carcinomas With Deficient DNA Mismatch Repair. Clin Gastroenterol Hepatol. 2016 Jul; 14 (7):1056-9 Epub 2016 Feb 17
    View PubMed
73. Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol. 2016 May; 14 (5):651-8 Epub 2016 Feb 09
    View PubMed
74. Ding X, Chaiteerakij R, Moser CD, Shaleh H, Boakye J, Chen G, Ndzengue A, Li Y, Zhou Y, Huang S, Sinicrope FA, Zou X, Thomas MB, Smith CD, Roberts LR. Antitumor effect of the novel sphingosine kinase 2 inhibitor abc294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells Oncotarget. 2016 Apr 12; 7(15):20080-92. Epub 1900 Jan 01.
    
75. Ding X, Chaiteerakij R, Moser CD, Shaleh H, Boakye J, Chen G, Ndzengue A, Li Y, Zhou Y, Huang S, Sinicrope FA, Zou X, Thomas MB, Smith CD, Roberts LR. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016 Apr 12; 7 (15):20080-92
    View PubMed
76. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26 (3):133-7
    View PubMed
77. Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65: (2)286-95.
    View PubMed
78. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algul H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Banhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolome A, Bassham DC, Bassi MT, Bast RC Jr, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR Jr, Becker C, Beckham JD, Bedard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Benard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Bockler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouche M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, et al, Chen CJ, Chen G, Chen P, Chen Q, Chen Q, Chen W, Cooper JM, Dong Z, Fan C, Fernandez-Zapico ME, Fiesel FC, Gao F, Ge L, Guo C, Harris AL, Her C, Hu D, Hu H, Hussain S, Jackson DJ, Jackson WT, Jiang H, Jiang H, Jiang Y, Jimenez A, Kim HY, Kim KW, Kim MM, Kumar D, Lee GM, Lee SJ, Lerman LO, Lewis PA, Li F, Liu Y, Lu B, Maeda A, Martin KR, Martinez J, McCormick C, Prince S, Ryan KM, Sanchez AM, Schulze RJ, Sharma S, Sinicrope FA, Sood AK, Springer W, Stevens C, Sun Y, Tang D, Venkatachalam K, Wang G, Wen X, Weyand CM, Wu GS, Xiao H, Xiao J, Xu X, Xu Z, Yu H, Yu Z, Yuan J, Zhang F, Zhang Y, Zhu W. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12 (1):1-222
    View PubMed
79. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015 Dec 1; 21 (23):5294-304 Epub 2015 July 17
    View PubMed
80. Kawakami H, Zaanan A, Sinicrope FA. Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol. 2015 Dec; 6 (6):676-84
    View PubMed
81. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst. 2015 Oct; 107 (10) Epub 2015 July 09
    View PubMed
82. Zaanan A, Okamoto K, Kawakami H, Khazaie K, Huang S, Sinicrope FA. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. J Biol Chem. 2015 Sep 25; 290 (39):23838-49 Epub 2015 Aug 05
    View PubMed
83. Zaanan A, Park JM, Tougeron D, Huang S, Wu TT, Foster NR, Sinicrope FA. Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. Int J Cancer. 2015 Sep 15; 137 (6):1498-502 Epub 2015 Mar 09
    View PubMed
84. Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, Buchanan DD, Casey G, Cleary SP, Cotterchio M, Farris AB, Figueiredo JC, Gallinger S, Green RC, Haile RW, Hopper JL, Jenkins MA, Le Marchand L, Makar KW, McLaughlin JR, Potter JD, Renehan AG, Sinicrope FA, Thibodeau SN, Ulrich CM, Win AK, Lindor NM, Limburg PJ. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24 (8):1229-38 Epub 2015 June 02
    View PubMed
85. Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015 Jul; 16 (7):30
    View PubMed
86. Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A. MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer. 2015 Jun 30; 113 (1):83-90 Epub 2015 June 02
    View PubMed
87. Okamoto K, Zaanan A, Kawakami H, Huang S, Sinicrope FA. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. Mol Cancer Res. 2015 Apr; 13 (4):659-69 Epub 2014 Dec 29
    View PubMed
88. Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015 Jan; 148 (1):77-87.e2 Epub 2014 Sept 30
    View PubMed
89. Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015 Jan; 148 (1):88-99 Epub 2014 Oct 08
    View PubMed
90. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014 Dec; 106 (12) Epub 2014 Nov 07
    View PubMed
91. Zaanan A, Bachet JB, Andre T, Sinicrope FA. Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer. Curr Colorectal Cancer Rep. 2014 Sep 1; 10 (3):346-353
    View PubMed
92. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106 (7) Epub 2014 June 12
    View PubMed
93. Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res. 2014 Jun 15; 20 (12):3319-27 Epub 2014 Apr 11
    View PubMed
94. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014 Jun; 13 (2):100-9 Epub 2013 Dec 28
    View PubMed
95. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014 Jun 1; 20 (11):3033-43 Epub 2014 Mar 31
    View PubMed
96. Tougeron D, Sha D, Manthravadi S, Sinicrope FA. Aspirin and colorectal cancer: back to the future. Clin Cancer Res. 2014 Mar 1; 20 (5):1087-94 Epub 2013 Dec 10
    View PubMed
97. Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 2014 Feb 1; 120 (3):415-24 Epub 2013 Oct 21
    View PubMed
98. Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica. 2014 Jan; 99 (1):60-9 Epub 2013 Aug 30
    View PubMed
99. Park JM, Tougeron D, Huang S, Okamoto K, Sinicrope FA. Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells. PLoS One. 2014; 9 (6):e100819 Epub 2014 June 23
    View PubMed
100. Graves KD, Sinicrope PS, Esplen MJ, Peterson SK, Patten CA, Lowery J, Sinicrope FA, Nigon SK, Borgen J, Gorin SS, Keogh LA, Lindor NM. Communication of genetic test results to family and health-care providers following disclosure of research results. Genet Med. 2014; 16(4):294-301.
     View PubMed
101. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014 Jan; 232(2):199-209.
     View PubMed
102. Huang S, Okamoto K, Yu C, Sinicrope FA. p62/sequestosome-1 up-regulation promotes ABT-263-induced caspase-8 aggregation/activation on the autophagosome. J Biol Chem. 2013 Nov 22; 288 (47):33654-33666 Epub 2013 Oct 11
     View PubMed
103. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013 Oct 10; 31 (29):3664-72 Epub 2013 Sept 09
     View PubMed
104. Sinicrope FA, Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, Shanmugam K, Grogan TM, Alberts SR, Shi Q. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer. 2013 Aug 1; 119 (15):2765-70 Epub 2013 May 08
     View PubMed
105. Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol. 2013 Jul; 11 (7):760-7; quiz e54-5 Epub 2012 Dec 23
     View PubMed
106. Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013 Apr 15; 119 (8):1528-36 Epub 2013 Jan 10
     View PubMed
107. Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther. 2013 Feb; 14 (2):100-7 Epub 2012 Nov 28
     View PubMed
108. Park JM, Huang S, Tougeron D, Sinicrope FA. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One. 2013; 8 (5):e65369 Epub 2013 May 28
     View PubMed
109. Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Honscheid P, Sinicrope FA, Tindall DJ, Muders MH, Datta K. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res. 2013 Jan 1; 73 (1):160-71 Epub 2012 Nov 13
     View PubMed
110. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012 Nov 10; 30 (32):3932-8 Epub 2012 Sept 17
     View PubMed
111. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012 Apr 4; 307 (13):1383-93
     View PubMed
112. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Banhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Bechet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronje MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Dong Z, et al, Garcia L, Ghosh P, Harris AL, Jackson WT, Jiang H, Jiang H, Jimenez A, Lee GM, Li F, McLean PJ, Prasad A, Reed JC, Ryan KM, Sanchez AM, Sinicrope FA, Sood AK, Springer W, Tang D, Wang F, Wang G, Wang J, Xu X, Yu L, Zhang J, Zhang XD, Zhu X. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8 (4):445-544
     View PubMed
113. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012 Mar 15; 18(6):1506-12. Epub 2012 Feb 02.
     View PubMed
114. Sinicrope PS, Goode EL, Limburg PJ, Vernon SW, Wick JB, Patten CA, Decker PA, Hanson AC, Smith CM, Beebe TJ, Sinicrope FA, Lindor NM, Brockman TA, Melton LJ 3rd, Petersen GM. A population-based study of prevalence and adherence trends in average risk colorectal cancer screening, 1997 to 2008. Cancer Epidemiol Biomarkers Prev. 2012 Feb; 21 (2):347-50 Epub 2011 Dec 05
     View PubMed
115. Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012 Feb 1; 30 (4):406-12 Epub 2011 Dec 27
     View PubMed
116. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15; 18 (2):546-54
     View PubMed
117. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012; 10:205. Epub 2012 Oct 03.
     View PubMed
118. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One. 2012; 7 (8):e42274 Epub 2012 Aug 06
     View PubMed
119. Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 1; 29 (34):4561-7 Epub 2011 Oct 11
     View PubMed
120. Huang S, Yang ZJ, Yu C, Sinicrope FA. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J Biol Chem. 2011 Nov 18; 286 (46):40002-12 Epub 2011 Sept 23
     View PubMed
121. Winawer SJ, Pasricha PJ, Schmiegel W, Sinicrope FA, Sung J, Seufferlein T, Kassem AM, Malekzadeh R, Kurtz RC, Classen M, Tytgat GN. The future role of the gastroenterologist in digestive oncology: an international perspective. Gastroenterology. 2011 Oct; 141(4):e13-21. Epub 2011 Aug 24.
     View PubMed
122. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011 Sep; 10 (9):1533-41 Epub 2011 Aug 30
     View PubMed
123. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011 Jun 8; 103 (11):863-75 Epub 2011 May 19
     View PubMed
124. Sinicrope FA, Broaddus R, Joshi N, Gerner E, Half E, Kirsch I, Lewin J, Morlan B, Hong WK. Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. Cancer Prev Res (Phila). 2011 Jun; 4(6):829-39.
     View PubMed
125. Sinicrope FA, Yang ZJ. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol. 2011 Mar; 7 (3):467-74
     View PubMed
126. Yang ZJ, Chee CE, Huang S, Sinicrope F. Autophagy modulation for cancer therapy. Cancer Biol Ther. 2011 Jan 15; 11 (2):169-76
     View PubMed
127. Sugumar A, Sinicrope FA. Serrated polyps of the colon. F1000 Med Rep. 2010 Dec 17; 2:89
     View PubMed
128. Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010 Dec; 85 (12):1080-9
     View PubMed
129. Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am. 2010 Sep; 39 (3):601-13
     View PubMed
130. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10; 28 (20):3219-26 Epub 2010 May 24
     View PubMed
131. Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC, O'Connell MJ, North Central Cancer Treatment Group. Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer. 2010 Apr 1; 116 (7):1691-8
     View PubMed
132. Sinicrope FA, Foster NR, Sargent DJ, O'Connell MJ, Rankin C. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010 Mar 15; 16 (6):1884-93 Epub 2010 Mar 09
     View PubMed
133. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2010 Mar; 7 (3):174-7
     View PubMed
134. Huang S, Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther. 2010 Mar; 9 (3):742-50 Epub 2010 Mar 02
     View PubMed
135. Sinicrope FA. Opinion: DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2010 Mar; 7(3):174-7.
     
136. Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, Gores GJ. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res. 2010 Mar 1; 70 (5):1960-9 Epub 2010 Feb 16
     View PubMed
137. Huang S, Sinicrope FA. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy. 2010 Feb; 6 (2):256-69 Epub 2010 Feb 06
     View PubMed
138. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer. 2010 Jan 5; 102 (1):165-72 Epub 2009 Dec 08
     View PubMed
139. Masuoka HC, Sinicrope FA. Clinical relevance of apoptotic regulatory proteins in colorectal cancers. Current Colorectal Cancer Reports. 2010; 6(3):111-7.
     
140. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009 Oct; 137 (4):1270-9 Epub 2009 July 03
     View PubMed
141. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol. 2009 Jul; 21 (4):369-73
     View PubMed
142. Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res. 2009 Jan 1; 15 (1):150-9
     View PubMed
143. Okumura K, Huang S, Sinicrope FA. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res. 2008 Dec 15; 14 (24):8132-42
     View PubMed
144. Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, Sargent DJ, Windschitl HE. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res. 2008 Sep 15; 14 (18):5810-8
     View PubMed
145. Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, Sargent DJ. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res. 2008 Jul 1; 14 (13):4128-33
     View PubMed
146. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008 Apr 15; 68 (8):2944-51
     View PubMed
147. Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus. 2008; 21 (3):241-50
     View PubMed
148. Half E, Sun Y, Sinicrope FA. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett. 2007 Jun 28; 251(2):237-46. Epub 2006 Dec 26.
     View PubMed
149. Sinicrope FA, Rego RL, Garrity-Park MM, Foster NR, Sargent DJ, Goldberg RM, Wiesenfeld M, Witzig TE, Thibodeau SN, Burgart LJ. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer. 2007 Mar 15; 120 (6):1232-8
     View PubMed
150. Half E, Sinicrope FA. Current status of colorectal cancer chemoprevention. Current Colorectal Cancer Reports. 2007; 3(1):39-48.
     
151. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN. Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol. 2006 Dec; 101: (12)2818-25.
     View PubMed
152. Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology. 2006 Sep; 131 (3):729-37
     View PubMed
153. Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):808-21. Epub 2006 Jun 22.
     View PubMed
154. Cohen G, Mustafi R, Chumsangsri A, Little N, Nathanson J, Cerda S, Jagadeeswaran S, Dougherty U, Joseph L, Hart J, Yerian L, Tretiakova M, Yuan W, Obara P, Khare S, Sinicrope FA, Fichera A, Boss GR, Carroll R, Bissonnette M. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res. 2006 Jun 1; 66(11):5656-64.
     View PubMed
155. Sinicrope FA. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog. 2006 Jun; 45(6):447-54.
     View PubMed
156. Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, La Plant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, Witzig TE, Thibodeau SN. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res. 2006 May 1; 12 (9):2738-44
     View PubMed
157. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem. 2006 Apr 28; 281 (17):11923-32 Epub 2006 Jan 30
     View PubMed
158. Sinicrope FA, Penington RC. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther. 2005 Oct; 4 (10):1475-83
     View PubMed
159. Alberts SR, Sinicrope FA, Grothey A. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer. 2005 Sep; 5 (3):211-3
     View PubMed
160. Gill S, Sinicrope FA. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol. 2005 Feb; 32(1):24-34.
     View PubMed
161. Sun Y, Sinicrope FA. Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther. 2005 Jan; 4 (1):51-9
     View PubMed
162. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res. 2004 Dec 15; 10 (24):8284-92
     View PubMed
163. Wargovich MJ, Chang P, Velasco M, Sinicrope F, Eisenbrodt E, Sellin J. Expression of cellular adhesion proteins and abnormal glycoproteins in human aberrant crypt foci. Appl Immunohistochem Mol Morphol. 2004 Dec; 12(4):350-5.
     
164. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC, Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):920-7.
     View PubMed
165. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004 Feb 10; 108(4):540-8.
     View PubMed
166. Half E, Sun Y, Danenberg K, Danenberg PV, Broaddus R, Ayers GD, Sinicrope FA. HER-2 expression and activation of colorectal cancer cell lines and human tumors: modulation by HER-2 receptor blockade. International Journal of Cancer. 2003.
     
167. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004 Jan-Jun; 23 (1-2):63-75
     View PubMed
168. Sun YJ, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002 Nov 1; 62(21):6323-8.
     View PubMed
169. Bismar MM, Sinicrope FA. Radiation enteritis. Curr Gastroenterol Rep. 2002 Oct; 4(5):361-5.
     View PubMed
170. Tang XM, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002 Sep 1; 62(17):4903-8.
     View PubMed
171. Sinicrope FA, Gwyn K. Chemoprevention of colorectal cancer. Am J Gastroenterol. 2002; 97:13-21.
     View PubMed
172. Tatabe S, Unate H, Sinicrope FA, Sakatani T, Sugamura K, Makino M, Ito H, Savaraj N, Kaibara N, Kuo MT. Expression of heavy subunit of y-Glutamylcysteine synthetase (y-GCSh) in human colorectal carcinoma. Int J Cancer. 2002; 97:21-7.
     View PubMed
173. Sample D, Sinicrope PS, Wargovich MJ, Sinicrope FA. Post study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2002; 11:281-5.
     View PubMed
174. Sample D, Wargovich MJ, Fischer SM, Inamdar N, Schwartz P, Wang X, Do, K-A, Sinicrope FA. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal PGE2 levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002; 11:275-9.
     View PubMed
175. Tatabe S, Sinicrope FA, Kuo MT. Induction of multidrug resistance protein MRP1and MRP3 and y-glutamylcystein synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002; 290:1427-33.
     View PubMed
176. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002; 62:1676-81.
     View PubMed
177. Boland CR, Sinicrope FA, Brenner D, Carethers J. Colorectal cancer prevention and treatment. Gastroenterology. 2000; 118:S115-S28.
     View PubMed
178. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa J-P. Aberrant methylation of the COX-2 CpG island in colorectal tumors. Cancer Res. 2000; 60:4044-8.
     View PubMed
179. Sinicrope FA, Roddey GR, McDonnell TJ, Shen Y, Stephens LC. Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res 1996 06. 1999-20; 2:1999-2006.
     
180. Frazier ML, Sinicrope FA, Amos CI, Cleary KR, Lynch PM, Luthra R. Loci for efficient detection of microsatellite instability in hereditary nonpolyposis colorectal cancer. Oncology Reports. 1999; 6:497-505.
     View PubMed
181. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg. 1999 May-Jun; 3(3):263-77.
     View PubMed
182. Sinicrope FA, Hart J, Lemoine M, Michelassi F, Lee JJ, Stephens LC. Apoptotic and mitotic indices predict patient survival rates in lymph node-negative colon carcinomas. Clin Cancer Res. 1999; 5:1793-804.
     View PubMed
183. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase-2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology. 1999; 117:350-8.
     View PubMed
184. Molina M, Anja-Buta M, Lemoine M, Xi L, Frazier M, Sinicrope FA. Increased cyclooxygenase-2 expression in pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999; 59:4356-62.
     View PubMed
185. Sinicrope FA, Roddey GR, LeMoine M, Frazier M, Stephens LC, Shen Y, Zhang W. Loss of p21WAF1/Cip1 protein expression accompanies neoplastic progression in the sporadic colorectal cancers but not HNPCCs. Clin Cancer Res. 1998; 4:1251-61.
     View PubMed
186. Sinicrope FA, Evans DB, Leach S, Cleary KR, Rich TA, Fenoglio C, Lee JJ, Abbruzzese JL. Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996; 2:2015-22.
     View PubMed
187. Sinicrope FA, Pazdur R, Levin B. Phase I evaluation of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy of colon carcinoma. Clin Cancer Res. 1996; 2:37-41.
     View PubMed
188. Al-Sabbagh R, Sinicrope FA, Sellin J, Roubein L. Short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol. 1996; 91:1814-16.
     View PubMed
189. Roubein LD, Lynch PM, Glober G, Sinicrope FA. Interobserver variability in endoscopic ultrasonography: a prospective evaluation. Gastrointest Endosc. 1996; 5:573-7.
     
190. Sinicrope FA, Ruan S, Cleary KR, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995; 55:237-41.
     View PubMed
191. Sinicrope FA, Sugarman S. Role of adjuvant therapy in surgically resected colorectal carcinoma. Gastroenterology. 1995; 109:984-93.
     View PubMed
192. Weber D, Dimopoulos M, Sinicrope FA, Alexanian R. VAD-cyclosporin therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1995; 19:159-63.
     View PubMed
193. Sinicrope FA, Hart J, Michelassi FM, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995; 1:1103-10.
     View PubMed
194. Sinicrope FA, Hart J, Michelassi F, Safa AR, Lee JJ, Brasitus TA. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer. 1994; 74:2908-17.
     View PubMed
195. Sinicrope FA, Levin B. Gastric cancer. Curr Opin in Gastroenterol. 1994; 10:610-17.
     
196. Sinicrope FA, Sugarman SM. Adjuvant therapy of colon carcinoma: current status and future directions. Cancer Bull. 1994; 46:344-51.
     
197. Sinicrope FA, Levin B. Gastric cancer. Curr Opin in Gastroenterol. 1993; 9:930-7.
     
198. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P- glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem. 1992; 267:24995-5002.
     View PubMed
199. Kavin H, Sinicrope FA, Esker AH. Perforation of the colon at endoscopy: a review. Am J Gastroenterology. 1992; 87:161-7.